Breaking News
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
January 16, 2018 - Aztec apocalypse found to be Salmonella outbreak
January 16, 2018 - Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy
January 16, 2018 - Three Ineffective Institutional Approaches to Quality Improvement in Healthcare
January 16, 2018 - New technology accelerates autism diagnosis and treatment
January 16, 2018 - Preterm babies likely to experience delays in auditory brain development, study reveals
January 16, 2018 - Research sheds new light on genetic, environmental factors that promote prostate cancer metastasis
January 16, 2018 - Mitochondrial impairment may actually protect the brain in Parkinson’s disease, study shows
January 15, 2018 - Energy drinks can have adverse health effects on youth, study reveals
January 15, 2018 - 60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
January 15, 2018 - Wanted: ‘Breathalyzer’ for Cannabis Use
January 15, 2018 - Surfers more likely to get antibiotic resistant E. coli in their guts
January 15, 2018 - “Baby brain” a real clinical entity finds study
January 15, 2018 - Whole of Britain to be put on a diet plan come March
January 15, 2018 - Neighborhood Deprivation Linked to Heart Failure
January 15, 2018 - Omega-3 and Omega-6 fatty acid intake may affect lupus outcomes
January 15, 2018 - Scientists discover new enzyme that could reduce obesity rates
January 15, 2018 - Evidence suggests two patterns of early symptoms precede and predict later BD risk
January 15, 2018 - Harm minimization approach for smoking cessation with e-cigarettes
January 15, 2018 - Surgery or Antibiotics for Appendicitis? Here’s What Patients Chose
January 15, 2018 - ASH: Frailty Screening Tool Guides Therapy in Elderly
January 15, 2018 - Study shows video games could cut dementia risk in seniors
January 15, 2018 - Common Food Additive Promoting C. diff?
January 15, 2018 - Mild traumatic brain injury causes long-term damage in mice
January 15, 2018 - Circadian clock proteins set the pace of plant growth
January 15, 2018 - Two proteins shown to regenerate brain in Parkinson’s disease
January 15, 2018 - Jotting down tasks may ease falling asleep, study says
January 15, 2018 - Chi-Med Initiates Fruquintinib U.S. Clinical Trials
January 15, 2018 - Cell-Free DNA May Help Pinpoint Breast Ca Survival
January 15, 2018 - What goes on inside a medically supervised injection facility?
January 15, 2018 - Research provides new model to better ascertain HIV mortality rates in Zambia
January 15, 2018 - Genetic analysis can enhance outcomes of depression treatment
January 15, 2018 - Variations in bacterial strains can trigger varying immune responses, study states
January 15, 2018 - TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
January 15, 2018 - HIV Vaccine Shows ‘Positive Signal’ in Small Study
January 15, 2018 - Researchers demonstrate RAS dimers are essential for cancer
January 15, 2018 - Groundbreaking report highlights plan to end bowel cancer
January 15, 2018 - Doc Aspires to Bring ‘Medicine the Musical’ to Off-Broadway
January 15, 2018 - Does an exploding brain network cause chronic pain?
January 15, 2018 - Researchers use novel PET tracer to assess myelin damage in mouse models of MS
January 15, 2018 - Survival strategy of mRNAs during sugar deficiency in the cell
January 15, 2018 - Hormone Therapy May Ease Depression Linked to Menopause
January 15, 2018 - Pain Sensitization Declines After Bariatric Tx in Obese Patients
January 15, 2018 - C7 nerve transfer improves function in spastic arm paralysis
January 15, 2018 - Australian kids are drinking and smoking far less than before
January 15, 2018 - Worsening of anxiety symptoms may be early indicator of Alzheimer’s disease
January 15, 2018 - Early testing for influenza symptoms can limit severe, life-threatening disease
January 15, 2018 - Exposure to estrogen-mimicking compounds may reverse effects of breast cancer treatment
January 15, 2018 - Lipids May Play Key Role in Abdominal Aneurysm
January 15, 2018 - Raw Dough’s a Raw Deal and Could Make You Sick
January 15, 2018 - Thinking about germs makes people concerned about how they look
January 15, 2018 - Pitt scientists develop new guidelines to alleviate EMS personnel fatigue
January 15, 2018 - Discovery suggests new approach for targeting most-wanted molecular culprits in cancer
January 14, 2018 - Rhizen Pharmaceuticals S.A. Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-Cell Lymphoma (PTCL)
January 14, 2018 - Adding Enzyme to Chemo Combo Improves Outcomes in Pancreatic CA
January 14, 2018 - Research suggests ways to help mentally ill in Ghana’s prayer camps
January 14, 2018 - U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer
January 14, 2018 - Availability of qualified nurses in hospitals affects patient satisfaction
January 14, 2018 - Prostate cancer’s gene-determined ‘immune landscape’ dictates tumor progression
January 14, 2018 - Online CME: Is This Your First Choice?
Researchers discover genetic mechanism for resistance to immunotherapy drugs

Researchers discover genetic mechanism for resistance to immunotherapy drugs

image_pdfDownload PDFimage_print

An urgent question for cancer scientists is why immunotherapy achieves dramatic results in some cases but doesn’t help most patients. Now, two research groups from Dana-Farber Cancer Institute have independently discovered a genetic mechanism in cancer cells that influences whether they resist or respond to immunotherapy drugs known as checkpoint inhibitors.

The scientists say the findings reveal potential new drug targets and might aid efforts to extend the benefits of immunotherapy treatment to more patients and additional types of cancer.

The discoveries are detailed in two articles published by the journal Science.

One report, focusing on clinical trial patients with advanced kidney cancer treated with checkpoint inhibitors, is from scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, led by Eliezer Van Allen, MD, of Dana-Farber and the Broad, and Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber.

The second report, identifies the immunotherapy resistance mechanism in melanoma cells, is from a group led by Kai Wucherpfennig, MD, PhD, director of Dana-Farber’s Center for Cancer Immunotherapy Research, and Shirley Liu, PhD, of Dana-Farber.

The two groups converged on a discovery that resistance to immune checkpoint blockade is critically controlled by changes in a group of proteins that regulate how DNA is packaged in cells. The collection of proteins, called a chromatin remodeling complex, is known as SWI/SNF; its components are encoded by different genes, among them ARID2, PBRM1, and BRD7. SWI/SNF’s job is to open up stretches of tightly wound DNA so that its blueprints can be read by the cell to activate certain genes to make proteins.

Researchers led by Van Allen and Choueiri sought an explanation for why some patients with a form of metastatic kidney cancer called clear cell renal cell cancer (ccRCC) gain clinical benefit – sometimes durable – from treatment with immune checkpoint inhibitors that block the PD-1 checkpoint, while other patients don’t.

The scientists’ curiosity was piqued by the fact that ccRCC differs from other types of cancer that respond well to immunotherapy, such as melanoma, non-small cell lung cancer, and a specific type of colorectal cancer. Cells of the latter cancer types contain many DNA mutations, which are thought to make distinctive “neoantigens” that help the patient’s immune system recognize and attack tumors, and make the cancer cells’ “microenvironment” hospitable to tumor-fighting T cells. By contrast, ccRCC kidney cancer cells contain few mutations, yet some patients even with advanced, metastatic disease respond well to immunotherapy.

To search for other characteristics of ccRCC tumors that influences immunotherapy response or resistance, the researchers used whole-exome DNA sequencing to analyze tumor samples from 35 patients treated in a clinical trial with the checkpoint blocker nivolumab (Opdivo). They also analyzed samples from another group of 63 patients with metastatic ccRCC treated with similar drugs.

When the data was sorted and refined, the scientists discovered that patients who benefited from the immunotherapy treatment with longer survival and progression-free survival were those whose tumors lacked a functioning PRBM1 gene. (About 41 percent of patients with ccRCC kidney cancer have a non-functioning PBRM1 gene.) That gene encodes a protein called BAF 180, which is a subunit of the PBAF subtype of the SWI/SNF chromatin remodeling complex.

Loss of the PBRM1 gene function caused the cancer cells to have increased expression of other genes, including gene pathway known as IL6/JAK-STAT3, which are involved in immune system stimulation.

While the finding does not directly lead to a test for immunotherapy response yet, Choueiri said, “We intend to look at these specific genomic alterations in larger, randomized controlled trials, and we hope that one day these findings will be the impetus for prospective clinical trials based on these alterations.”

In the second report, the scientists led by Wucherpfennig came at the issue from a different angle. They used the gene-editing CRISPR/Cas9 technique to sift the genomes of melanoma cells for changes that made tumors resistant to being killed by immune T cells, which are the main actors in the immune system response against infections and cancer cells.

The search turned up about 100 genes which appeared to govern melanoma cells’ resistance to being killed by T cells. Inactivating those genes rendered the cancer cells sensitive to T-cell killing. Narrowing down their search, the Wucherpfennig team identified the PBAF subtype of the SWI/SNF chromatin remodeling complex – the same group of proteins implicated by the Van Allen and Choueiri team in kidney cancer cells – as being involved in resistance to immune T cells.

When the PBRM1 gene was knocked out in experiments, the melanoma cells became more sensitive to interferon-gamma produced by T cells, and in response produced signaling molecules that recruited more tumor-fighting T cells into the tumor. The two other genes in the PBAF complex – ARID2 and BRD7 – are also found mutated in some cancers, according to the researchers, and those cancers, like the melanoma lacking ARID2 function, may also respond better to checkpoint blockade. The protein products of these genes, the authors note, “represent targets for immunotherapy, because inactivating mutations sensitize tumor cells to T-cell mediated attack.” Finding ways to alter those target molecules, they add, “will be important to extend the benefit of immunotherapy to larger patient populations, including cancers that thus far are refractory to immunotherapy.”

Source:

http://www.dana-farber.org/newsroom/news-releases/2018/mechanism-for-resistance-to-immunotherapy-treatment-discovered/

Tagged with:

About author

Related Articles